 Shares of Lineage Cell Therapeutics, Inc. NASDAQ:LCTX have been given a consensus broker rating score of 1.40 Strong Buy from the five brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and four have issued a strong buy rating on the ... 